Pharmaceutical manufacturers of Itraconazole

Piramal Group has interests in a portfolio of businesses including financial services (Piramal Enterprises Limited), pharmaceuticals (Piramal Pharma Limited), and real estate (Piramal Realty). With operations in 30 countries and brand presence in over 100 markets, the Group’s turnover is ~$1.9 billion in FY 2022. Driven by its core values, the Group pursues inclusive growth, while adhering to ethical and value-driven practices. Piramal Foundation has initiatives in primary healthcare, nutrition, water, and social sector ecosystems.

Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Intas is committed to challenging the unmet medical and societal needs through a comprehensive pharmaceutical value chain spanning across the world. Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare to operate in global markets. Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year. It is currently present in more than 85 countries worldwide with robust sales, marketing and distribution infrastructure in markets like North America, Europe, Central & Latin America, Asia-Pacific as well as CIS and MENA countries. Intas’ remarkable success in North America and European operations have helped us emerge as a global brand in the world’s largest pharmaceutical markets.

Since our inception in 2006, Titan Laboratories has focused on formulating new-age solutions in diversified spectrums of Pellets, Granules, Tablets and Capsule manufacturing. With the expertise of such widespread specialties, we at Titan Laboratories take great pride in our proficiency in providing Quality Analytical Services that focus on the formulation & packaging of both solid and semi-solid finished products. Backed by our holistic approach towards catering to multifarious integrated services, we aim to meet the concept-to-commercialization needs of our customers while providing quality pellets, granules or finish formulations.

Lee Pharma Limited was established in 1997 in India it is a research-driven company with a critical focus on the development, synthesis, and commercialization of new products and cost-effective processes. ​ We manufacture several intermediate chemicals, Active Pharmaceutical Ingredients & Semi-finished Dosage Forms (Pellets & Granules), and Finished Formulations. Our expertise in the field won us, numerous clients, in India as well as across the globe. Lee Pharma Manufacturing facilities are approved by several international regulatory bodies such as USFDA, EUGMP, WHO GMP etc.

VIATRIS™ represents a fresh approach to healthcare, dedicated to ensuring medicine accessibility, promoting sustainable practices, pioneering creative remedies, and enhancing patient results. Founded in 2020 through the merger of Mylan and Upjohn, Viatris unites top-notch scientific, production and distribution skills with established regulatory, medical and commercial proficiencies.

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere.

Glenmark Pharmaceuticals Limited is a global pharmaceutical company based in Mumbai, India. The company focuses on developing and manufacturing generic and innovative drugs. Their therapeutic areas of expertise include dermatology, respiratory, and oncology. They also manufacture high-quality affordable generic products for the US and European markets through Glenmark Life Sciences, an independent unit of Glenmark Pharmaceuticals.

Granules India Limited is a rapidly expanding pharmaceutical company with top-notch amenities for APIs, PFIs and Finished Dosages, catering to clients in more than 60 nations. We are dedicated to upholding high standards in production, excellence and client relations. Our main office is situated in Hyderabad, and we also have branches in the United States, United Kingdom, Colombia and China, as well as production facilities in India and China.

Dream that drives us at Nosch. The laudable goal that we aim for. The vision that suffuses us with the passion to innovate and excel. Over the past twenty one years, we have been ceaselessly engaged in a quest to sustain and improve the quality of life through creating safe pharmaceutical solutions. Our competencies have grown to embrace the entire pharmaceutical value chain-APIs and semi-finished Formulations. Today, with an impeccable reputation for uncompromising quality and timely delivery, Nosch has emerged as the partner of choice across the world.

Established in 1984, Neuland Laboratories Limited is a publicly traded company based in Hyderabad, India. The organization offers solutions throughout the entire range of the pharmaceutical industry's chemical needs, from synthesizing library compounds to providing NCEs and advanced intermediates at different stages in the clinical life cycle, as well as for commercial launch. Neuland's specialty lies in the production of APIs and advanced intermediates from its facilities approved by the USFDA. Its primary expertise is the application of effective process chemistry to manufacturing in a compliant regulatory setting.

SMS Lifesciences India Limited, headquartered in Hyderabad, India, is a research-driven company with over three decades of experience. It is a public listed leading API manufacturer, supplying to major generic and innovator firms. With a focus on APIs, the company operates four state-of-the-art facilities and provides quality alternative manufacturing solutions to multinational companies for their contract research and manufacturing needs. The company has multiple manufacturing facilities supporting a wide range and capacity of APIs and Intermediates.

The organization is engaged in the production of API’s, Intermediates, and semi-processed formulations. Its manufacturing facilities have been inspected by global regulatory authorities such as USFDA, EDQM, PMDA, KFDA & Cofepris (Mexican MOH). The products are shipped worldwide and have a strong presence in regulated markets including the USA, Japan & Europe etc. It operates six manufacturing facilities situated in Andhra Pradesh & Telangana, with an annual turnover of 100 Million USD. The company's credit rating has been improved by ‘India Ratings Pvt. Ltd. (100% subsidiary of Fitch).

Aurore Life Sciences is a specialized manufacturer of active pharmaceutical ingredients (API) with a varied range of capabilities to enhance efficiency for generic pharmaceutical companies worldwide. Established in 2017 by a team with extensive expertise throughout the pharmaceutical supply chain, the company is dedicated to becoming the most favored partner for pharmaceuticals. At Aurore, we strive to innovate in the production and delivery of dependable high-quality products, earning the trust of both customers and regulatory bodies. Our focus on rapidly expanding capabilities has driven us to acquire, integrate, and extend our presence across multiple regions.

Glenmark Life Sciences Limited is a prominent producer and developer of specialized, high-value, non-generic, active pharmaceutical ingredients (APIs) within chronic therapeutic fields such as heart disease, disorders of the central nervous system, pain management, and diabetes. The corporation is progressively offering CDMO services to various multinational and specialized pharmaceutical firms. It maintains a varied collection of over 137 compounds and delivers its merchandise to clients in India, Europe, North America, Latin America, Japan, and other parts of the globe (ROW).

Nifty Labs Private Limited was established in March 2005. The corporation has specialized in the production of Active Pharmaceutical Ingredients (APIs) and advanced Intermediates for APIs.

Hanmi has experienced notable expansion since its establishment in 1973 and has emerged as the most prominent company among pharmaceutical firms in South Korea. We take pride in being recognized as a global frontrunner in the production of high-quality API for cephalosporins, cardiovascular, anti-diabetic, gastrointestinal, and CNS medications. The facilities have undergone inspection and received approval from UK MHRA, German BSG, Australian TGA, and US FDA. Hanmi has successfully developed and introduced new combination drugs and a series of IMDs using its patented process

Società Italiana Medicinali Scandicci, known as S.I.M.S. srl, was established in Scandicci in 1937 by Mr Ugo Rangoni. During the 1950s and 1960s, it experienced growth in both production and personnel. In 1972, the first DMF (phenylbutazone) was presented to the FDA. The current API facility in Reggello has been operational since 1974 and has been regularly examined by the Agency ever since. Since the 1980s, the company has garnered increasing recognition in the field of custom-toll manufacturing through GMP status with major partners. The company has more than 20 APIs with registered DMF and, when applicable, the corresponding CEP.

Zim offers innovative solutions for administering medications, focusing on enhancing patient convenience and compliance. The company utilizes its own advanced technologies, such as modified release and taste masking, to create and produce distinct pharmaceutical products. Their range includes oral solid dosage formulations and pre-formulations (PFI), encompassing tablets, capsules, dry syrups, pellets, granules, and orally disintegrating strips (ODS). Additionally, they provide services for site transfer/variation for sustained release tablets, oral disintegrating tablets, fast disintegrating capsules, and more.

Daewoong Bio Inc., a standalone affiliate of the Daewoong Group located in Seoul, South Korea, was established in 1983. Daewoong Bio manufactures world-class products that comply with cGMP standards under quality assurance systems. As a primary producer, Daewoong Bio supplies APIs for worldwide distribution and multinational enterprises developing innovative products. Daewoong Bio is also a comprehensive pharmaceutical company that employs its internal research and development, production facilities, and experienced marketing team along with external global connections. Daewoong Bio specializes in the production of top-notch antibiotic APIs and general APIs.